1
|
Jamgochian M, Shah RR, Yeh C, Kurtyka D, Ouellette S, Rao B. Adapting with the Pandemic: Modified Mohs Micrographic Surgery Using Rim and Deep Margin Technique. THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY 2024; 17:33-35. [PMID: 38912199 PMCID: PMC11189643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/25/2024]
Abstract
The COVID-19 pandemic has changed many facets of medical care and has resulted in a rise in delayed treatments across all specialties, including cosmetic dermatology. Delayed care for squamous cell carcinomas (SCC) and basal cell carcinoma (BCC) is not only a burden for medical providers, but also confers a risk to patients, as delayed surgeries are associated with increased metastatic risk and tumor size. Mohs micrographic surgery (MMS) delayed by more than one year leads to increased risk of complications, including bleeding and impaired wound healing, especially in the elderly population. To decrease bleeding risks, we have developed a modified MMS technique known as the "rim and deep margin" technique. Here, we present additional cases using this technique to minimize bleeding and operative time for patients with an increased risk of morbidity. This technique has been used successfully in the past for large tumors and can now be used for patients who have faced delay of care, as evidenced by its success during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Marielle Jamgochian
- Drs. Jamgochian and Rao and Ms. Ouellette are with Department of Dermatology, Rutgers Robert Wood Johnson Medical School in Piscataway, New Jersey
| | - Rohan R. Shah
- Dr. Yeh and Mr. Shah are with Department of Dermatology, Rutgers New Jersey Medical School in Newark, New Jersey
| | - Christopher Yeh
- Dr. Yeh and Mr. Shah are with Department of Dermatology, Rutgers New Jersey Medical School in Newark, New Jersey
| | - David Kurtyka
- Dr. Kurtyka is with the Thomas Jefferson Department of Dermatology and Cutaneous Biology in Philadelphia, Pennsylvania
| | - Sam Ouellette
- Drs. Jamgochian and Rao and Ms. Ouellette are with Department of Dermatology, Rutgers Robert Wood Johnson Medical School in Piscataway, New Jersey
| | - Babar Rao
- Drs. Jamgochian and Rao and Ms. Ouellette are with Department of Dermatology, Rutgers Robert Wood Johnson Medical School in Piscataway, New Jersey
| |
Collapse
|
2
|
Song JS, Smith SP, Stucken CL. Implications of Malignancy, Radiation, and Timing of Major Nasal Reconstruction. Facial Plast Surg Clin North Am 2024; 32:189-198. [PMID: 38575277 DOI: 10.1016/j.fsc.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
Owing to the complex, multilayered anatomy of the nose in the central face, major nasal reconstruction can pose a significant challenge for reconstructive surgeons. It is the responsibility of reconstructive surgeons to have an understanding of the most common cutaneous malignancies and excisional techniques that may lead to complex nasal defects. The purpose of this article is to discuss these malignancies, excisional techniques, and impacts of radiation on tissue that has implications for reconstructive surgeons.
Collapse
Affiliation(s)
- Jin Soo Song
- Smith Facial Plastics, Columbus Ohio, 725 Buckles Court North #210, Gahanna, OH 43230, USA
| | - Stephen P Smith
- Smith Facial Plastics, Columbus Ohio, 725 Buckles Court North #210, Gahanna, OH 43230, USA
| | - Chaz L Stucken
- Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
| |
Collapse
|
3
|
Sinclair R, Wong XL, Shumack S, Baker C, MacMahon B. The role of micrometastasis in high-risk skin cancers. Australas J Dermatol 2024; 65:143-152. [PMID: 38156714 DOI: 10.1111/ajd.14206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 10/30/2023] [Accepted: 12/15/2023] [Indexed: 01/03/2024]
Abstract
The propensity to metastasize is the most important prognostic indicator for solid cancers. New insights into the mechanisms of early carcinogenesis have revealed micrometastases are generated far earlier than previously thought. Evidence supports a synergistic relationship between vascular and lymphatic seeding which can occur before there is clinical evidence of a primary tumour. Early vascular seeding prepares distal sites for colonisation while regional lymphatics are co-opted to promote facilitative cancer cell mutations. In response, the host mounts a global inflammatory and immunomodulatory response towards these cells supporting the concept that cancer is a systemic disease. Cancer staging systems should be refined to better reflect cancer cell loads in various tissue compartments while clinical perspectives should be broadened to encompass this view when approaching high-risk cancers. Measured adjunctive therapies implemented earlier for low-volume, in-transit cancer offers the prospect of preventing advanced disease and the need for heroic therapeutic interventions. This review seeks to re-appraise how we view the metastatic process for solid cancers. It will explore in-transit metastasis in the context of high-risk skin cancer and how it dictates disease progression. It will also discuss how these implications will influence our current staging systems and its consequences on management.
Collapse
Affiliation(s)
- Robert Sinclair
- Queensland Institute of Dermatology, Brisbane, QLD, Australia
| | - Xin Lin Wong
- St George Dermatology and Skin Cancer Centre, New South Wales, Kogarah, Australia
| | - Stephen Shumack
- St George Dermatology and Skin Cancer Centre, New South Wales, Kogarah, Australia
- Department of Dermatology, Royal North Shore Hospital, New South Wales, Sydney, Australia
| | - Christopher Baker
- Department of Dermatology, St Vincents Hospital, Victoria, Melbourne, Australia
| | | |
Collapse
|
4
|
Muir J, Morton SK, Ozluer S. Field cancerisation and radiotherapy: a case of treatment complications. Med J Aust 2023; 219:335. [PMID: 37604651 DOI: 10.5694/mja2.52085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 08/08/2023] [Indexed: 08/23/2023]
Affiliation(s)
- James Muir
- Mater Hospital Brisbane, Brisbane, QLD
- University of Queensland, Brisbane, QLD
| | | | | |
Collapse
|
5
|
Dobre EG, Surcel M, Constantin C, Ilie MA, Caruntu A, Caruntu C, Neagu M. Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts. Int J Mol Sci 2023; 24:1079. [PMID: 36674595 PMCID: PMC9866322 DOI: 10.3390/ijms24021079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 01/02/2023] [Accepted: 01/03/2023] [Indexed: 01/08/2023] Open
Abstract
Early diagnosis is essential for completely eradicating skin cancer and maximizing patients' clinical benefits. Emerging optical imaging modalities such as reflectance confocal microscopy (RCM), optical coherence tomography (OCT), magnetic resonance imaging (MRI), near-infrared (NIR) bioimaging, positron emission tomography (PET), and their combinations provide non-invasive imaging data that may help in the early detection of cutaneous tumors and surgical planning. Hence, they seem appropriate for observing dynamic processes such as blood flow, immune cell activation, and tumor energy metabolism, which may be relevant for disease evolution. This review discusses the latest technological and methodological advances in imaging techniques that may be applied for skin cancer detection and monitoring. In the first instance, we will describe the principle and prospective clinical applications of the most commonly used imaging techniques, highlighting the challenges and opportunities of their implementation in the clinical setting. We will also highlight how imaging techniques may complement the molecular and histological approaches in sharpening the non-invasive skin characterization, laying the ground for more personalized approaches in skin cancer patients.
Collapse
Affiliation(s)
- Elena-Georgiana Dobre
- Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania
| | - Mihaela Surcel
- Immunology Department, “Victor Babes” National Institute of Pathology, 050096 Bucharest, Romania
| | - Carolina Constantin
- Immunology Department, “Victor Babes” National Institute of Pathology, 050096 Bucharest, Romania
- Department of Pathology, Colentina University Hospital, 020125 Bucharest, Romania
| | | | - Ana Caruntu
- Department of Oral and Maxillofacial Surgery, “Carol Davila” Central Military Emergency Hospital, 010825 Bucharest, Romania
- Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania
| | - Constantin Caruntu
- Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Dermatology, “Prof. N.C. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania
| | - Monica Neagu
- Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania
- Immunology Department, “Victor Babes” National Institute of Pathology, 050096 Bucharest, Romania
- Department of Pathology, Colentina University Hospital, 020125 Bucharest, Romania
| |
Collapse
|
6
|
Pendlebury GA, Bongiorno MA, Lackey JN. Aggressive Cutaneous Squamous Cell Carcinomas Following Treatment for Graft-versus-Host Disease: A Case Report and Review of Risk Factors. Dermatopathology (Basel) 2022; 9:122-130. [PMID: 35466244 PMCID: PMC9036292 DOI: 10.3390/dermatopathology9020015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 03/20/2022] [Accepted: 03/28/2022] [Indexed: 02/04/2023] Open
Abstract
A 19-year-old female with a history of pre-B cell acute lymphocytic leukemia (ALL) presented with two aggressive cutaneous squamous cell carcinomas (C-SCC) in the right hand. The patient was diagnosed with pre-B cell ALL at four years of age. She underwent chemotherapy with initial remission. However, recurrence of the pre-B cell ALL required an unrelated allogeneic cord hematopoietic stem cell transplant (alloHSCT). Post-transplant, the patient developed Graft-Versus-Host Disease (GVHD), which was treated with immunosuppressant therapy for six years until resolution. Fourteen years following the transplant, the patient developed a morbilliform drug eruption secondary to clindamycin. She consequently received prednisone treatment. During the treatment period, the patient developed a new ulcerated and tender nodule on the dorsal aspect of her right hand. Further histopathological biopsy confirmed the diagnosis of C-SCC, which required excision. Ten months following the excision, the patient developed an additional C-SCC nodule on the same right hand, separated by 2.6 cm from the prior C-SCC. She was referred for a ray resection procedure. This case illustrates a patient with multiple risk factors that may have contributed to the continued development of C-SCC. Such risk factors include: a prolonged course of immunosuppressant medications and voriconazole treatment. Additional research is needed to investigate the etiologies and risks of C-SCC development in patients who require a transplant and long-duration immunosuppressive therapy.
Collapse
Affiliation(s)
- Gehan A. Pendlebury
- College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
- Correspondence:
| | - Michelle A. Bongiorno
- Department of Dermatology, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA;
| | - Jeffrey N. Lackey
- Department of Dermatology, Tulane University School of Medicine, New Orleans, LA 70112, USA;
| |
Collapse
|
7
|
Membrive Conejo I, Pera Cegarra O, Foro Arnalot P, Reig Castillejo A, Rodríguez de Dios N, Sanz Latiesas X, Deza G, Quera Jordana J, Fernandez-Velilla Cepria E, Martínez Moñino A, Liu Cheng F, Algara López M. High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years-single institution experience. Clin Transl Oncol 2022; 24:578-585. [PMID: 34698997 PMCID: PMC8885494 DOI: 10.1007/s12094-021-02718-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 09/18/2021] [Indexed: 11/17/2022]
Abstract
PURPOSE Our center adopted high-dose-rate brachytherapy with surface applicators (plesiotherapy) in 2008, creating custom molds to treat irregular areas. This study describes the efficacy and safety outcomes after extensive follow-up in the patients. METHODS/PATIENTS We planned the treatment using two computed tomography (CT) scans: the first to delineate the lesion and the second after placing the thermoplastic mold. Fusing the two CT images enables planning of the target volume and pinpointing, where the catheters are in the mold. RESULTS Seventy patients received plesiotherapy, either exclusively or following excision in patients with risk factors for recurrence. Those receiving plesiotherapy alone showed a complete response rate of 95.8%, and recurrences occurred in 5.7% at a mean follow-up of 96.2 months. Chronic toxicity appeared in 26.6% of patients, but severity was limited to grade 1 or 2. CONCLUSIONS High-dose-rate brachytherapy with customized molds yields a high rate of complete response, with long-term recurrence rates in line with similar studies and an acceptable toxicity rate.
Collapse
Affiliation(s)
- I Membrive Conejo
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain.
- Pompeu Fabra University, Barcelona, Spain.
| | - O Pera Cegarra
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
| | - P Foro Arnalot
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
| | - A Reig Castillejo
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
| | - N Rodríguez de Dios
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
| | - X Sanz Latiesas
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
| | - G Deza
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
- Dermatology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | - J Quera Jordana
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
| | - E Fernandez-Velilla Cepria
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
| | - A Martínez Moñino
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
| | - F Liu Cheng
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
| | - M Algara López
- Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain
- Institut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain
- Universitat Autónoma de Barcelona, Barcelona, Spain
| |
Collapse
|
8
|
Ferrari G, Pang LY, De Moliner F, Vendrell M, Reardon RJM, Higgins AJ, Chopra S, Argyle DJ. Effective Penetration of a Liposomal Formulation of Bleomycin through Ex-Vivo Skin Explants from Two Different Species. Cancers (Basel) 2022; 14:cancers14041083. [PMID: 35205831 PMCID: PMC8870439 DOI: 10.3390/cancers14041083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Revised: 02/09/2022] [Accepted: 02/14/2022] [Indexed: 01/25/2023] Open
Abstract
Bleomycin is a chemotherapy agent that, when administered systemically, can cause severe pulmonary toxicity. Bleosome is a novel formulation of bleomycin encapsulated in ultra-deformable (UD) liposomes that may be applicable as a topical chemotherapy for diseases such as non-melanoma skin cancer. To date, the ability of Bleosome to effectively penetrate through the skin has not been evaluated. In this study, we investigated the ability of Bleosome to penetrate through ex vivo skin explants from dogs and horses. We visualized the penetration of UD liposomes through the skin by transmission electron microscopy. However, to effectively image the drug itself we fluorescently labeled bleomycin prior to encapsulation within liposomes and utilized multiphoton microscopy. We showed that UD liposomes do not penetrate beyond the stratum corneum, whereas bleomycin is released from UD liposomes and can penetrate to the deeper layers of the epidermis. This is the first study to show that Bleosome can effectively penetrate through the skin. We speculate that UD liposomes are penetration enhancers in that UD liposomes carry bleomycin through the outer skin to the stratum corneum and then release the drug, allowing diffusion into the deeper layers. Our results are comparative in dogs and horses and warrant further studies on the efficacy of Bleosome as topical treatment.
Collapse
Affiliation(s)
- Giulia Ferrari
- Roslin Institute, The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, UK; (G.F.); (R.J.M.R.); (D.J.A.)
| | - Lisa Y. Pang
- Roslin Institute, The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, UK; (G.F.); (R.J.M.R.); (D.J.A.)
- Correspondence: ; Tel.: +44-13-1651-9164
| | - Fabio De Moliner
- Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK; (F.D.M.); (M.V.)
| | - Marc Vendrell
- Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK; (F.D.M.); (M.V.)
| | - Richard J. M. Reardon
- Roslin Institute, The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, UK; (G.F.); (R.J.M.R.); (D.J.A.)
| | | | - Sunil Chopra
- The London Dermatology Centre, London W1G 8AS, UK; (A.J.H.); (S.C.)
| | - David J. Argyle
- Roslin Institute, The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, UK; (G.F.); (R.J.M.R.); (D.J.A.)
| |
Collapse
|
9
|
Li Z, Wei J, Zheng H, Zhang Y, Song M, Cao H, Jin Y. The new horizon of biomarker in melanoma patients: A study based on autophagy-related long non-coding RNA. Medicine (Baltimore) 2022; 101:e28553. [PMID: 35029926 PMCID: PMC8735716 DOI: 10.1097/md.0000000000028553] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Accepted: 12/22/2021] [Indexed: 12/24/2022] Open
Abstract
Autophagy-related long non-coding RNAs (arlncRNAs) play a crucial role in the pathogenesis and development of the tumor. However, there is a lack of systematic analysis of arlncRNAs in melanoma patients.Melanoma data for analysis were obtained from The Cancer Genome Atlas (TCGA) database. By establishing a co-expression network of autophagy-related mRNAs-lncRNAs, we identified arlncRNAs in melanoma patients. We evaluated the prognostic value of arlncRNAs by univariate and multivariate Cox analysis and constructed an arlncRNAs risk model. Patients were divided into high- and low-risk groups based on the arlncRNAs risk score. This model was evaluated by Kaplan-Meier (K-M) analysis, univariate-multivariate Cox regression analysis, and receiver operating characteristic (ROC) curve analysis. Characteristics of autophagy genes and co-expressive tendency were analyzed by principal component analysis and Gene Set Enrichment Analysis (GSEA) functional annotation.Nine arlncRNAs (USP30-AS1, LINC00665, PCED1B-AS1, LINC00324, LINC01871, ZEB1-AS1, LINC01527, AC018553.1, and HLA-DQB1-AS1) were identified to be related to the prognosis of melanoma patients. Otherwise, the 9 arlncRNAs constituted an arlncRNAs prognostic risk model. K-M analysis and ROC curve analysis showed that the arlncRNAs risk model has good discrimination. Univariate and multivariate Cox regression analysis showed that arlncRNAs risk model was an independent prognostic factor in melanoma patients. Principal component analysis and GSEA functional annotation showed different autophagy and carcinogenic status in the high- and low-risk groups.This novel arlncRNAs risk model plays an essential role in predicting of the prognosis of melanoma patients. The model reveals new prognosis-related biomarkers for autophagy, promotes precision medicine, and provides a lurking target for melanoma's autophagy-related treatment.
Collapse
Affiliation(s)
- Zhehong Li
- Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| | - Junqiang Wei
- Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| | - Honghong Zheng
- General surgery department, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| | - Yafang Zhang
- Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| | - Mingze Song
- Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| | - Haiying Cao
- Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| | - Yu Jin
- Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
| |
Collapse
|
10
|
Mokoala KM, Lawal IO, Vorster M, Sathekge MM. Radionuclide Therapy of Skin Cancers and Bowen's Disease Using A Specially Designed Rhenium Cream. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00067-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
11
|
Pêtre A, Pommier P, Brahmi T, Chabaud S, King S, Fayette J, Neidhart EM, Amini-Adle M. Benefit from adjuvant radiotherapy according to the number of risk factors in cutaneous squamous cell carcinoma. Radiother Oncol 2022; 168:53-60. [DOI: 10.1016/j.radonc.2022.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/28/2021] [Accepted: 01/14/2022] [Indexed: 11/24/2022]
|